Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Rani Therapeutics Has Entered Into A Definitive Agreement With ProGen For The Co-development And Commercialization Of RT-114, An Oral Ranipill Capsule Containing ProGen's PG-102, A GLP-1/GLP-2 Dual Agonist, For Obesity
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commercialization of RT-114 worldwide, including a 50/50 cost and revenue share arrangement. Rani has exclusive rights to lead development and commercialization of RT-114 in the United States, Europe, Canada and Australia, and ProGen has exclusive rights to lead development and commercialization in the rest of the world. Each party has certain rights to sublicense in its territories. Rani is designated to lead operationally in conducting preclinical and development activities through the Phase 1 program, which is expected to initiate in 2025. As part of this agreement, there is no upfront payment or financial exchange between the companies.
根據合作協議，Rani和保力進控股同意分享全球範圍內RT-114的開發和商業化責任，包括一項50/50的成本和營業收入分配安排。Rani在美國、歐洲、加拿大和澳洲擁有開發和商業化RT-114的獨家權利，而保力進控股則在其他地區擁有這方面的獨家權利。每一方都有在自己領土內授權的特定權利。Rani被指定爲在進行預臨床和開發活動的操作上領先，該項目預計於2025年啓動第一階段計劃。根據協議，公司之間沒有預付款或者財務交易。
